Crucell: Investors

Home | Contact | Search | Site Map

About Us

	Corporate Profile
	Share Information
	Financial Information
	Press Releases
	Event Calendar
	Presentations
	Shareholder Services
	Investor Relations Contact
	Crucell's press releases are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader. If you are new to RSS, we suggest you read the Introduction to RSS article.

Dutch German

2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2003 \| 2002 \| 2001 \| 2000

24 Dec 2002	Centocor returns rights to anti-CD46 antibody to Crucell
23 Dec 2002	Crucell Expects Charge Related to Impairment of Goodwill
20 Dec 2002	Cambridge Antibody Technology and Crucell Settle Patent Dispute
19 Dec 2002	Biotech Alliance of DSM Biologics and Crucell - for faster preparation of new medicines at lower cost
05 Nov 2002	Crucell Appoints Director Corporate Communications
14 Oct 2002	Crucell and the US National Institutes of Health Sign Contract for Production of Ebola, Marburg and Lassa Vaccines for Use in Human Clinical Trials
14 Oct 2002	Crucell Revenues EUR 2.0 million in Third Quarter 2002
04 Oct 2002	Invitation Conference Call Q3 Results 2002
03 Oct 2002	Crucell to Webcast Presentation at UBS Warburg Global Life Sciences Conference
01 Oct 2002	Crucell and Applied Molecular Evolution Sign PER.C6(TM) Antibody Production Agreement
09 Sep 2002	Crucell announces management changes
05 Sep 2002	Crucell Signs PER.C6(TM) Agreement with NatImmune
16 Aug 2002	Crucell and Johns Hopkins Announce Research Agreement for Antibodies against LCH
12 Aug 2002	Crucell Signs PER.C6(TM) Licensing Agreement with GenVec
07 Aug 2002	Crucell and NIH Extend Ebola Vaccine Agreement to include Marburg and Lassa Vaccines
19 Jul 2002	Crucell Appoints Dr. Jaap Goudsmit to Executive Committee
15 Jul 2002	Crucell Increases Second Quarter 2002 Revenues by 131%
08 Jul 2002	Crucell maintains earlier profit statements
03 Jul 2002	Crucell and Genexine Announce Agreement
04 Jun 2002	Crucell to Webcast Presentation at the Needham & Company Biotech Conference
29 May 2002	Crucell signs PER.C6TM license with MedImmune
16 May 2002	Crucell and NIH to develop ebola vaccine
15 Apr 2002	Crucell's first quarter 2002 revenues increase 135%
10 Apr 2002	Rhein Biotech and Crucell enter into PER.C6 License agreement
05 Mar 2002	Crucell: preliminary Phase I data of PER.C6-derived HIV vaccine encouraging
04 Mar 2002	Crucell spin-out Galapagos Genomics NV to complete a private placement
01 Feb 2002	First milestone achieved in Centocor-Crucell agreement for CD46 human antibodies against cancer
24 Jan 2002	Invitation Conference Call Annual Results
23 Jan 2002	Crucell and Innogenetics announce PER.C6 deal for the development and manufacturing of antibodies
17 Jan 2002	Crucell appoints VP Development and Regulatory Affairs
15 Jan 2002	Lexigen signs on as Crucell's 19th PER.C6 licensee
10 Jan 2002	PER.C6 manufacturing services available in United States